Advertisement

Coronary Artery Stenting

  • Michela Faggioni
  • Eric A. Heller
  • George D. DangasEmail author
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

When Andreas Gruentzig performed the first percutaneous coronary angioplasty on an awake patient in 1977 (Zurich, Switzerland), he created the nascent field of interventional cardiology and ushered in a new era of coronary revascularization. Percutaneous coronary transluminal angioplasty (PTCA) was positioned to serve as an alternative and complement to coronary artery bypass grafting (CABG) and optimal medical therapy. As in many medical fields, the advancement of percutaneous coronary intervention (PCI) has been punctuated by innovations and pitfalls. Nevertheless, indication for PCI has broadened in the past 10 years, and the number of catheterization laboratories has increased to face the changes in the treatment strategies of patients with coronary artery disease (CAD).

Keywords

Angioplasty Drug-eluting stent Bare-metal stent In-stent thrombosis Reperfusion 

References

  1. 1.
    Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496–501. PubMed PMID: 8041414.CrossRefGoogle Scholar
  2. 2.
    Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489–95. PubMed PMID: 8041413.CrossRefGoogle Scholar
  3. 3.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122. PubMed PMID: 22070834.CrossRefGoogle Scholar
  4. 4.
    Jang JS, Song YJ, Kang W, Jin HY, Seo JS, Yang TH, et al. Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: a meta-analysis. JACC Cardiovasc Interv. 2014;7(3):233–43. PubMed PMID: 24529934.CrossRefGoogle Scholar
  5. 5.
    Kern MJ, Donohue TJ, Aguirre FV, Bach RG, Caracciolo EA, Wolford T, et al. Clinical outcome of deferring angioplasty in patients with normal translesional pressure-flow velocity measurements. J Am Coll Cardiol. 1995;25(1):178–87. PubMed PMID: 7798498.CrossRefGoogle Scholar
  6. 6.
    Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334(26):1703–8. PubMed PMID: 8637515.CrossRefGoogle Scholar
  7. 7.
    Bech GJ, De Bruyne B, Bonnier HJ, Bartunek J, Wijns W, Peels K, et al. Long-term follow-up after deferral of percutaneous transluminal coronary angioplasty of intermediate stenosis on the basis of coronary pressure measurement. J Am Coll Cardiol. 1998;31(4):841–7. PubMed PMID: 9525557.CrossRefGoogle Scholar
  8. 8.
    Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. J Am Coll Cardiol. 2007;49(21):2105–11. PubMed PMID: 17531660.CrossRefGoogle Scholar
  9. 9.
    Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol. 2007;49(8):839–48. PubMed PMID: 17320741.CrossRefGoogle Scholar
  10. 10.
    Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24. PubMed PMID: 19144937.CrossRefGoogle Scholar
  11. 11.
    De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001. PubMed PMID: 22924638.CrossRefGoogle Scholar
  12. 12.
    Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344–426. PubMed PMID: 25249585.Google Scholar
  13. 13.
    Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–87. PubMed PMID: 11419424.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354(9180):708–15. PubMed PMID: 10475181.
  15. 15.
    Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360(9335):743–51. PubMed PMID: 12241831.CrossRefGoogle Scholar
  16. 16.
    Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165–75. PubMed PMID: 19458363.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908–17. PubMed PMID: 15956636.CrossRefGoogle Scholar
  18. 18.
    Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–25. PubMed PMID: 17010789.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353(11):1095–104. PubMed PMID: 16162880.CrossRefGoogle Scholar
  20. 20.
    Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55(22):2435–45. PubMed PMID: 20359842.CrossRefGoogle Scholar
  21. 21.
    Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, et al. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol. 2007;49(8):849–54. PubMed PMID: 17320742.CrossRefGoogle Scholar
  22. 22.
    Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol. 2016;67(3):264–72. PubMed PMID: 26796390.CrossRefGoogle Scholar
  23. 23.
    Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72. PubMed PMID: 19228612.CrossRefGoogle Scholar
  24. 24.
    He JQ, Gao YC, Yu XP, Zhang XL, Luo YW, Wu CY, et al. Syntax score predicts clinical outcome in patients with three-vessel coronary artery disease undergoing percutaneous coronary intervention. Chin Med J. 2011;124(5):704–9. PubMed PMID: 21518562.Google Scholar
  25. 25.
    Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213–22. PubMed PMID: 25775087.CrossRefGoogle Scholar
  26. 26.
    Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278(23):2093–8. PubMed PMID: 9403425.CrossRefGoogle Scholar
  27. 27.
    Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733–42. PubMed PMID: 12930925.CrossRefGoogle Scholar
  28. 28.
    Thune JJ, Hoefsten DE, Lindholm MG, Mortensen LS, Andersen HR, Nielsen TT, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005;112(13):2017–21. PubMed PMID: 16186438.CrossRefGoogle Scholar
  29. 29.
    Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53(18):1677–89. PubMed PMID: 19406344.CrossRefGoogle Scholar
  30. 30.
    Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706–13. PubMed PMID: 17901079.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–30. PubMed PMID: 18499566.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Philip F, Stewart S, Southard JA. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: network meta-analysis of randomized primary percutaneous coronary intervention trials. Catheter Cardiovasc Interv. 2016;88(1):38–48. PubMed PMID: 26916633.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82(1):E1–27. PubMed PMID: 23299937.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115–23. PubMed PMID: 23991625.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65(10):963–72. PubMed PMID: 25766941. Pubmed Central PMCID: 4359051.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Bangalore S, Toklu B, Wetterslev J. Complete versus culprit-only revascularization for ST-segment-elevation myocardial infarction and multivessel disease: a meta-analysis and trial sequential analysis of randomized trials. Circ Cardiovasc Interv. 2015;8(4). PubMed PMID: 25873730.
  37. 37.
    Villablanca PA, Briceno DF, Massera D, Hlinomaz O, Lombardo M, Bortnick AE, et al. Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized trials. Int J Cardiol. 2016;220:251–9. PubMed PMID: 27390938.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ellis SG, da Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation. 1994;90(5):2280–4. PubMed PMID: 7955184.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296–329. PubMed PMID: 18071078.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16. PubMed PMID: 21463150. Pubmed Central PMCID: 3415273.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350(9076):461–8. PubMed PMID: 9274581.
  42. 42.
    Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43(10):1743–51. PubMed PMID: 15145093.CrossRefGoogle Scholar
  43. 43.
    Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16. PubMed PMID: 17387127.CrossRefGoogle Scholar
  44. 44.
    Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91. PubMed PMID: 18268144.CrossRefGoogle Scholar
  45. 45.
    Epstein SE, Waksman R, Pichard AD, Kent KM, Panza JA. Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum. JACC Cardiovasc Interv. 2013;6(10):993–8. PubMed PMID: 24156960.CrossRefGoogle Scholar
  46. 46.
    Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5(4):476–90. PubMed PMID: 22872053.CrossRefGoogle Scholar
  47. 47.
    Willerson JT. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. Circulation. 1996;94(6):1194. PubMed PMID: 8822965.CrossRefGoogle Scholar
  48. 48.
    Starkey IR. The RITA trial. Lancet. 1993;341(8851):1020. PubMed PMID: 8096894.Google Scholar
  49. 49.
    Sculpher MJ, Seed P, Henderson RA, Buxton MJ, Pocock SJ, Parker J, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet. 1994;344(8927):927–30. PubMed PMID: 7934351.CrossRefGoogle Scholar
  50. 50.
    First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet. 1995;346(8984):1179–84. PubMed PMID: 7475656.
  51. 51.
    Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117–24. PubMed PMID: 11297702.CrossRefGoogle Scholar
  52. 52.
    So SI. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002;360(9338):965–70. PubMed PMID: 12383664.CrossRefGoogle Scholar
  53. 53.
    van den Brand MJ, Rensing BJ, Morel MA, Foley DP, de Valk V, Breeman A, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol. 2002;39(4):559–64. PubMed PMID: 11849851.CrossRefGoogle Scholar
  54. 54.
    Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008;118(4):381–8. PubMed PMID: 18606919.CrossRefGoogle Scholar
  55. 55.
    Valgimigli M, Dawkins K, Macaya C, de Bruyne B, Teiger E, Fajadet J, et al. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial. J Am Coll Cardiol. 2007;49(4):431–41. PubMed PMID: 17258088.CrossRefGoogle Scholar
  56. 56.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1996;335(4):217–25. PubMed PMID: 8657237.Google Scholar
  57. 57.
    Group BDS, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15. PubMed PMID: 19502645. Pubmed Central PMCID: 2863990.CrossRefGoogle Scholar
  58. 58.
    Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84. PubMed PMID: 23121323.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64(18):1929–49. PubMed PMID: 25077860.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164. PubMed PMID: 23182125.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation. 2009;119(9):1330–52. PubMed PMID: 19131581.CrossRefGoogle Scholar
  62. 62.
    Anderson HV. Appropriateness of percutaneous coronary intervention: are we acting appropriately? JAMA Cardiol. 2016;1(2):224–5. PubMed PMID: 27437897.CrossRefGoogle Scholar
  63. 63.
    Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. PubMed PMID: 25399658. Pubmed Central PMCID: 4481318.PubMedCentralCrossRefPubMedGoogle Scholar
  64. 64.
    Bonaca MP, Braunwald E, Sabatine MS. Long-term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373(13):1274–5. PubMed PMID: 26398078.Google Scholar
  65. 65.
    Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in ischemic events with Ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732–40. PubMed PMID: 27046160.CrossRefGoogle Scholar
  66. 66.
    Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382(9906):1714–22. PubMed PMID: 24004642.CrossRefGoogle Scholar
  67. 67.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15. PubMed PMID: 17982182.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556–66. PubMed PMID: 20513595.CrossRefGoogle Scholar
  69. 69.
    Dangas GD, Claessen BE, Mehran R, Xu K, Fahy M, Parise H, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv. 2012;5(11):1097–105. PubMed PMID: 23174632.CrossRefGoogle Scholar
  70. 70.
    Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67(19):2224–34. PubMed PMID: 27079334.CrossRefGoogle Scholar
  71. 71.
    Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. J Am Coll Cardiol. 2016;67(21):2492–502. PubMed PMID: 27046159.CrossRefGoogle Scholar
  72. 72.
    Stefanini GG, Windecker S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv. 2012;5(3):332–5. PubMed PMID: 22715449.CrossRefGoogle Scholar
  73. 73.
    Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125(9):1110–21. PubMed PMID: 22302840.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375(9710):201–9. PubMed PMID: 20060578.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (clinical evaluation of the Xience V Everolimus eluting coronary stent system in the treatment of patients with De novo native coronary artery lesions). JACC Cardiovasc Interv. 2013;6(9):914–22. PubMed PMID: 24050859.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277–89. PubMed PMID: 26825231.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–8. PubMed PMID: 10545431.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115(22):2842–7. PubMed PMID: 17515458.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165–71. PubMed PMID: 15644543.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152–60. PubMed PMID: 16750678.CrossRefGoogle Scholar
  81. 81.
    Moscarella E, Varricchio A, Stabile E, Latib A, Ielasi A, Tespili M, et al. Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian experience. Int J Cardiol. 2015;199:366–72. PubMed PMID: 26241643.CrossRefGoogle Scholar
  82. 82.
    Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989–97. PubMed PMID: 17296825.CrossRefGoogle Scholar
  83. 83.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51. PubMed PMID: 17470709.CrossRefGoogle Scholar
  84. 84.
    Kim YS, Lee SR. Successful prasugrel therapy for recurrent left main stent thrombosis in a clopidogrel hyporesponder. Tex Heart Inst J. 2015;42(5):483–6. PubMed PMID: 26504448. Pubmed Central PMCID: 4591894.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013;128(10):1055–65. PubMed PMID: 23900047.CrossRefGoogle Scholar
  86. 86.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51(12):1181–7. PubMed PMID: 18355656.CrossRefGoogle Scholar
  87. 87.
    Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114(8):798–806. PubMed PMID: 16908773.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michela Faggioni
    • 1
    • 2
  • Eric A. Heller
    • 3
  • George D. Dangas
    • 4
    Email author
  1. 1.Mount Sinai HeartMount Sinai Medical CenterNew YorkUSA
  2. 2.Cardiothoracic Department, Division of CardiologyUniversity Hospital of PisaPisaItaly
  3. 3.Columbia University Medical CenterNew YorkUSA
  4. 4.Cardiovascular InnovationMount Sinai Medical CenterNew YorkUSA

Personalised recommendations